The Quantellect read.As of Nov 19, 2026, 6 active firms cover Jasper Therapeutics Inc: 3 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $1.50 to $7.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $3.38 sits 71% below the current $11.76. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.75 next quarter toward $-21.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Neutral
Strong Buy00%
Buy350%
Neutral350%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$3.38
-71.3% downside
Average target across 4 active firms as of Nov 19, 2026 vs $11.76 current
Highest Target$7.00
Average Target$3.38
Lowest Target$1.50
Detailed analyst forecasts for JSPR
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 3 of 6 active firms rate JSPR a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
JSPR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.75
Range $-0.75 – $-0.75 · 1 analysts · +38% YoY
Next period, 1 analysts expect Jasper Therapeutics Inc to earn $-0.75 a share (range $-0.75 – $-0.75), versus $-0.54 a year earlier. Full-year consensus is $-6.90, growing to $-21.15 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $6.0M, rising to $0 next year.
Top analysts covering Jasper Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JSPR.
#1
Leonid Timashev
RBC Capital · Rank #27
Neutral
$3.00-74.5% to target
Overall win rate
52%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$6.00-49.0% to target
Overall win rate
51%
+ Follow
#3
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Neutral
No targeton JSPR
Overall win rate
35%
+ Follow
#4
Jay Olson
Oppenheimer · Rank #484
Buy
$65.00+452.7% to target
Overall win rate
31%
+ Follow
#5
Justin Zelin
BTIG · Rank #495
Buy
$210.00+1685.7% to target
Overall win rate
30%
+ Follow
JSPR stock forecast FAQ
What is JSPR's average 12-month price target?+
The 4 active firms with a live target average $3.38 for Jasper Therapeutics Inc over the next 12 months, ranging from a $7.00 high to a $1.50 low, as of Nov 19, 2026.
Is JSPR stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 6 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for JSPR?+
The Street-high target is $7.00 (Evercore ISI Group), and the Street-low is $1.50 (UBS). The average of all 4 active-firm targets is $3.38.
How many active Wall Street firms cover JSPR?+
6 active firms have a recognized rating on Jasper Therapeutics Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering JSPR?+
Among analysts who currently cover JSPR, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Neutral with a $3.00 target.
What is Jasper Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.75 per share (range $-0.75 – $-0.75) across 1 analysts. Full-year EPS is projected at $-6.90, rising to $-21.15 the following year.
How much revenue is Jasper Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $6.0M, growing to $0 next year.
Have analysts been upgrading or downgrading JSPR lately?+
As of Nov 19, 2026, 3 of 6 active firms rate JSPR a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JSPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.